{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:31:10Z","timestamp":1792513870282,"version":"4.5.0"},"reference-count":34,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precision Oncology"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Case reports and small prospective trials suggest that administering targeted therapies to patients with advanced cancer and an identified genomic target may be associated with clinical benefit. The Targeted Agent and Profiling Utilization Registry (TAPUR) study, a phase II prospective, nonrandomized, multibasket pragmatic clinical trial, aims to identify signals of drug activity when US Food and Drug Administration\u2013approved drugs are matched to prespecified genomic targets in patients with advanced cancer, outside of approved indications. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p> Patients eligible to participate in TAPUR are age \u2265 12 years and have advanced measurable or evaluable solid tumors, multiple myeloma, or B-cell non-Hodgkin lymphoma. Eligible participants are matched to any of the 16 US Food and Drug Administration\u2013approved study drugs based on protocol-specified genomic inclusion and exclusion criteria. Genomic profiling from any Clinical Laboratory Improvement Amendments\u2013certified, College of American Pathologists\u2013accredited laboratory is acceptable. The treating physician selects the treatment from the available study therapies or consults with the TAPUR Molecular Tumor Board. Participants are placed into multiple parallel cohorts defined by tumor type, genomic alteration, and drug. The primary study end point within each cohort is objective response or stable disease of at least 16 weeks duration. Secondary end points include safety, progression-free survival, and overall survival. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> More than 1,000 participants have thus far been registered, and more than 800 have been treated with a TAPUR study drug. Two study cohorts have permanently closed to enrollment because of lack of antitumor activity, and 12 have expanded to the second stage of enrollment after promising preliminary activity. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> The TAPUR study will describe the efficacy and toxicity of the targeted drugs used outside of their approved indications when matched to a somatic genomic variant. <\/jats:p><\/jats:sec>","DOI":"10.1200\/po.18.00122","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T19:59:44Z","timestamp":1531339184000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":125,"title":["Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study"],"prefix":"10.1200","author":[{"given":"Pam K.","family":"Mangat","sequence":"first","affiliation":[{"name":"Pam K. Mangat, Suanna S. Bruinooge, Elizabeth Garrett-Mayer, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan Halabi, Duke University Medical Center, Durham; Edward S. Kim, Carolinas HealthCare System\u2019s Levine Cancer Institute, Charlotte, NC; Ajjai Alva, University of Michigan; Jane Perlmutter, Gemini Group, Ann Arbor; Philip J. Stella, Michigan Cancer Research Consortium, Ypsilanti; Kathleen J. Yost, Cancer Research Consortium of West Michigan, Grand Rapids, MI;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[{"name":"Pam K. Mangat, Suanna S. Bruinooge, Elizabeth Garrett-Mayer, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan Halabi, Duke University Medical Center, Durham; Edward S. Kim, Carolinas HealthCare System\u2019s Levine Cancer Institute, Charlotte, NC; Ajjai Alva, University of Michigan; Jane Perlmutter, Gemini Group, Ann Arbor; Philip J. Stella, Michigan Cancer Research Consortium, Ypsilanti; Kathleen J. Yost, Cancer Research Consortium of West Michigan, Grand Rapids, MI;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suanna S.","family":"Bruinooge","sequence":"additional","affiliation":[{"name":"Pam K. Mangat, Suanna S. Bruinooge, Elizabeth Garrett-Mayer, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan Halabi, Duke University Medical Center, Durham; Edward S. Kim, Carolinas HealthCare System\u2019s Levine Cancer Institute, Charlotte, NC; Ajjai Alva, University of Michigan; Jane Perlmutter, Gemini Group, Ann Arbor; Philip J. Stella, Michigan Cancer Research Consortium, Ypsilanti; Kathleen J. Yost, Cancer Research Consortium of West Michigan, Grand Rapids, MI;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Garrett-Mayer","sequence":"additional","affiliation":[{"name":"Pam K. Mangat, Suanna S. Bruinooge, Elizabeth Garrett-Mayer, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan Halabi, Duke University Medical Center, Durham; Edward S. Kim, Carolinas HealthCare System\u2019s Levine Cancer Institute, Charlotte, NC; Ajjai Alva, University of Michigan; Jane Perlmutter, Gemini Group, Ann Arbor; Philip J. Stella, Michigan Cancer Research Consortium, Ypsilanti; Kathleen J. Yost, Cancer Research Consortium of West Michigan, Grand Rapids, MI;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajjai","family":"Alva","sequence":"additional","affiliation":[{"name":"Pam K. Mangat, Suanna S. Bruinooge, Elizabeth Garrett-Mayer, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan Halabi, Duke University Medical Center, Durham; Edward S. Kim, Carolinas HealthCare System\u2019s Levine Cancer Institute, Charlotte, NC; Ajjai Alva, University of Michigan; Jane Perlmutter, Gemini Group, Ann Arbor; Philip J. Stella, Michigan Cancer Research Consortium, Ypsilanti; Kathleen J. Yost, Cancer Research Consortium of West Michigan, Grand Rapids, MI;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Janeway","sequence":"additional","affiliation":[{"name":"Pam K. Mangat, Suanna S. Bruinooge, Elizabeth Garrett-Mayer, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan Halabi, Duke University Medical Center, Durham; Edward S. Kim, Carolinas HealthCare System\u2019s Levine Cancer Institute, Charlotte, NC; Ajjai Alva, University of Michigan; Jane Perlmutter, Gemini Group, Ann Arbor; Philip J. Stella, Michigan Cancer Research Consortium, Ypsilanti; Kathleen J. Yost, Cancer Research Consortium of West Michigan, Grand Rapids, MI;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Stella","sequence":"additional","affiliation":[{"name":"Pam K. Mangat, Suanna S. Bruinooge, Elizabeth Garrett-Mayer, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan Halabi, Duke University Medical Center, Durham; Edward S. Kim, Carolinas HealthCare System\u2019s Levine Cancer Institute, Charlotte, NC; Ajjai Alva, University of Michigan; Jane Perlmutter, Gemini Group, Ann Arbor; Philip J. Stella, Michigan Cancer Research Consortium, Ypsilanti; Kathleen J. Yost, Cancer Research Consortium of West Michigan, Grand Rapids, MI;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile","family":"Voest","sequence":"additional","affiliation":[{"name":"Pam K. Mangat, Suanna S. Bruinooge, Elizabeth Garrett-Mayer, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan Halabi, Duke University Medical Center, Durham; Edward S. Kim, Carolinas HealthCare System\u2019s Levine Cancer Institute, Charlotte, NC; Ajjai Alva, University of Michigan; Jane Perlmutter, Gemini Group, Ann Arbor; Philip J. Stella, Michigan Cancer Research Consortium, Ypsilanti; Kathleen J. Yost, Cancer Research Consortium of West Michigan, Grand Rapids, MI;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen J.","family":"Yost","sequence":"additional","affiliation":[{"name":"Pam K. Mangat, Suanna S. Bruinooge, Elizabeth Garrett-Mayer, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan Halabi, Duke University Medical Center, Durham; Edward S. Kim, Carolinas HealthCare System\u2019s Levine Cancer Institute, Charlotte, NC; Ajjai Alva, University of Michigan; Jane Perlmutter, Gemini Group, Ann Arbor; Philip J. Stella, Michigan Cancer Research Consortium, Ypsilanti; Kathleen J. Yost, Cancer Research Consortium of West Michigan, Grand Rapids, MI;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Perlmutter","sequence":"additional","affiliation":[{"name":"Pam K. Mangat, Suanna S. Bruinooge, Elizabeth Garrett-Mayer, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan Halabi, Duke University Medical Center, Durham; Edward S. Kim, Carolinas HealthCare System\u2019s Levine Cancer Institute, Charlotte, NC; Ajjai Alva, University of Michigan; Jane Perlmutter, Gemini Group, Ann Arbor; Philip J. Stella, Michigan Cancer Research Consortium, Ypsilanti; Kathleen J. Yost, Cancer Research Consortium of West Michigan, Grand Rapids, MI;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Pinto","sequence":"additional","affiliation":[{"name":"Pam K. Mangat, Suanna S. Bruinooge, Elizabeth Garrett-Mayer, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan Halabi, Duke University Medical Center, Durham; Edward S. Kim, Carolinas HealthCare System\u2019s Levine Cancer Institute, Charlotte, NC; Ajjai Alva, University of Michigan; Jane Perlmutter, Gemini Group, Ann Arbor; Philip J. Stella, Michigan Cancer Research Consortium, Ypsilanti; Kathleen J. Yost, Cancer Research Consortium of West Michigan, Grand Rapids, MI;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward S.","family":"Kim","sequence":"additional","affiliation":[{"name":"Pam K. Mangat, Suanna S. Bruinooge, Elizabeth Garrett-Mayer, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan Halabi, Duke University Medical Center, Durham; Edward S. Kim, Carolinas HealthCare System\u2019s Levine Cancer Institute, Charlotte, NC; Ajjai Alva, University of Michigan; Jane Perlmutter, Gemini Group, Ann Arbor; Philip J. Stella, Michigan Cancer Research Consortium, Ypsilanti; Kathleen J. Yost, Cancer Research Consortium of West Michigan, Grand Rapids, MI;..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Schilsky","sequence":"additional","affiliation":[{"name":"Pam K. Mangat, Suanna S. Bruinooge, Elizabeth Garrett-Mayer, and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Susan Halabi, Duke University Medical Center, Durham; Edward S. Kim, Carolinas HealthCare System\u2019s Levine Cancer Institute, Charlotte, NC; Ajjai Alva, University of Michigan; Jane Perlmutter, Gemini Group, Ann Arbor; Philip J. Stella, Michigan Cancer Research Consortium, Ypsilanti; Kathleen J. Yost, Cancer Research Consortium of West Michigan, Grand Rapids, MI;..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3741"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0353"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.6143"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.7739"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.186"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.5740"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.11057"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1627"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2014.06.004"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.47"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv253"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.5997"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0603"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1396"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10606"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.011486"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00188-6"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.5229"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404582"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7916"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3123"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502309"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3780"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO.18.00122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T07:02:58Z","timestamp":1653807778000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO.18.00122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1200\/PO.18.00122"],"URL":"https:\/\/doi.org\/10.1200\/po.18.00122","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"2018-07-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}